BioCentury
ARTICLE | Company News

Medivir, J&J sales and marketing update

December 23, 2013 8:00 AM UTC

Johnson & Johnson launched simeprevir to treat chronic HCV genotype 1 infection as Olysio in the U.S., as Galexos in Canada and as Sovriad in Japan. In the U.S., Olysio has a wholesale acquisition cost of $22,120 for 28 tablets of the 150 mg dose. According to Olysio's label, the dose is recommended once daily for 12 weeks in combination with pegylated interferon and ribavirin, followed by either 12 or 36 additional weeks of interferon and ribavirin, depending on prior response status. ...